Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585625 | 0.98 | PGK1 (0.46) | PGK1PGK2ACP3HIF1ASRC | |
| SCHEMBL1585621 | 0.98 | PGK1 (0.46) | PGK1PGK2ACP3HIF1ASRC | |
| SCHEMBL16499027 | 0.83 | SRC (0.46) | PGK1PGK2SRC | |
| SCHEMBL17915889 | 0.83 | LIPG (0.41) | HIF1ASRCLIPG | |
| SCHEMBL1585622 | 0.81 | SRC (0.39) | HIF1ASRCLIPG | |
| SCHEMBL16499213 | 0.81 | HIF1A (0.46) | PGK1PGK2HIF1A | |
| SCHEMBL9102020 | 0.78 | ACP3 (0.54) | PGK1PGK2ACP3 | |
| SCHEMBL17612624 | 0.78 | AKT2 (0.40) | PGK1PGK2 | |
| SCHEMBL16514556 | 0.77 | PTPN5 (0.50) | PGK1PGK2HIF1A | |
| SCHEMBL9104617 | 0.77 | EGLN1 (0.48) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | PGK1 1613/4885PGK2 1758/4885ACP3 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.